A recent study by Future Market Insights projects significant growth in the global clinical chemistry enzymes market, forecasting an expansion at a compound annual growth rate (CAGR) of 5.9% over the next decade. Valued at US$ 3.1 billion at the end of 2022, the market is expected to climb to US$ 3.2 billion in 2023, marking a 5.3% year-over-year increase. By 2033, this figure is anticipated to reach approximately US$ 5.7 billion.
Clinical chemistry enzymes are critical in the field of clinical diagnostics, playing a key role in the measurement of various analytes essential for disease diagnosis, ongoing monitoring, and research. As the prevalence of chronic illnesses such as diabetes, cardiovascular diseases, and cancer continues to rise globally, so too does the demand for clinical chemistry testing. Enzymes, as integral components of diagnostic assays, are instrumental in measuring biomarkers related to these health conditions, thereby driving market growth.
Request a Sample copy of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-17807
The shift toward personalized medicine has increased the need for precise and reliable diagnostic tests. Clinical chemistry enzymes play a crucial role in measuring specific biomarkers for personalized treatment decisions. The demand for personalized medicine and targeted therapies has contributed to the growth of the clinical chemistry enzymes market.
Key players in the clinical chemistry enzymes market often engage in strategic collaborations, partnerships, and acquisitions to enhance their product portfolios, expand their market presence, and develop innovative enzyme solutions. These collaborations contribute to the overall market growth.
Key Takeaways:
- By enzyme type, acid phosphatase – ACP accounts for US$ 411.8 million in 2022. Acid phosphatase is commonly used as a biomarker to assess prostate health.
- By application, diagnostics purpose accounts for US$ 2.0 Billion in 2022. Clinical chemistry enzymes are essential biomarkers used for the early detection and diagnosis of various diseases and medical conditions
- Hospitals held more than 35.6% of the global market share in 2022. Hospitals handle a large volume of patients for diagnostic testing on a daily basis
- By region, North America held dominant share in world in 2022. The increasing frequency of various liver illnesses will drive market expansion in North America.
Request Report Methodology: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17807
Market Competition:
The clinical chemistry enzymes market is highly competitive, with key players including Thermo Fisher Scientific. These companies are constantly participating conferences, award competition with their products and launching new products to gain a larger market share, with a focus on affordability, convenience, and effectiveness.
- In September 2021, Thermo Fisher Scientific has announced the availability of their fully automated analyzers, which are intended primarily for applications involving enzyme assays.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the clinical chemistry enzymes market in its latest study, presenting a historical demand assessment of 2017 – 2022 and projections for 2023 – 2033. The global clinical chemistry enzymes market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader
Key Companies Profiled:
- Takara Bio, Inc.
- Promega Corporation
- Enzo Life Sciences, Inc.
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- Creative Enzyme
- F. Hoffmann-La Roche Ltd.
- Solis BioDyne.
- Ambliqon A/S.
- ekf Diagnostics
- Abbot
- Sekisui Diagnostics
- Aldevron
- Codexis Inc.
Clinical Chemistry Enzymes Market Segmentation:
By Enzyme Type:
- Acid Phosphatase – ACP
- Alanine Amino-Transferase – ALT/GPT
- Alkaline Phosphatase – ALP
- Aspartate Amino-Transferase – AST/GOT
- Cholinesterase – CHE
- Creatine Kinase – CK
- Creatine Kinase MB – CK-MB
- Gamma Glutamyltransferase – GGT
- Glutamate Dehydrogenase – GLDH
- Hydroxybutyrate Dehydrogenase – HBDH
- Lactate Dehydrogenase – LDH
- Lipase – LIP
By Application:
- Diagnostics Purpose
- Therapeutic Purpose
- Analytical purpose
By End User:
- Hospitals
- Diagnostics/Pathology Labs
- Ambulatory Surgical Centers
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/17807
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube